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Abstract
Background: In order to facilitate multinational clinical research, regulatory requirements need to become
international and harmonised. The EU introduced the Directive 2001/20/EC in 2004, regulating investigational
medicinal products in Europe.
Methods: We conducted a survey in order to identify the national regulatory requirements for major categories of
clinical research in ten European Clinical Research Infrastructures Network (ECRIN) countries-Austria, Denmark,
France, Germany, Hungary, Ireland, Italy, Spain, Sweden, and United Kingdom-covering approximately 70% of the
EU population. Here we describe the results for regulatory requirements for typical investigational medicinal
products, in the ten countries.
Results: Our results show that the ten countries have fairly harmonised definitions of typical investigational
medicinal products. Clinical trials assessing typical investigational medicinal products require authorisation from a
national competent authority in each of the countries surveyed. The opinion of the competent authorities is
communicated to the trial sponsor within the same timelines, i.e., no more than 60 days, in all ten countries. The
authority to which the application has to be sent to in the different countries is not fully harmonised.
Conclusion: The Directive 2001/20/EC defined the term ‘investigational medicinal product’ and all regulatory
requirements described therein are applicable to investigational medicinal products. Our survey showed, however,
that those requirements had been adopted in ten European countries, not for investigational medicinal products
overall, but rather a narrower category which we term ‘typical’ investigational medicinal products. The result is
partial EU harmonisation of requirements and a relatively navigable landscape for the sponsor regarding typical
investigational medicinal products.
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Clinical trials are studies conducted with human trial
participants with the intention to increase knowledge
about how well a diagnostic test or therapeutic interven-
tion works in a particular population. Randomised clini-
cal trials are the most stringent type of clinical research
to determine efficacy and safety, only surpassed by sys-
tematic reviews of such trials [1-4]. However, most clini-
cal trials are conducted using inadequate methodologies
and involve too few participants [5-12]. This raises the
risks of systematic errors and random errors. The tasks
for clinical research are further challenged by the neces-
sity to study the impact of different genetic subgroups on
the intervention effect [13,14]. The summed conse-
quences are that we need extensive research collabora-
tion to secure adequate methodologies and sufficiently
large participant numbers [15,16]. One way to attack
these problems is to conduct multinational clinical trials.
Multinational clinical trials require the sponsor to
navigate multiple legislative systems and regulatory
environments. The objective of the Directive 2001/20/
EC was to harmonise clinical trial regulations within the
EU member states for investigational medicinal products
[17]. The opposite effect has been alluded to in a num-
ber of articles and reports, citing evidence that the
implementation of the Directive 2001/20/EC resulted in
divergences at the national level and increased complex-
ity in conducting both national as well as multinational
clinical trials [18-26].
Knowledge of the different national regulatory require-
ments is an essential prerequisite for conducting multina-
tional clinical research, and whereas the larger commercial
companies have such provisions, the academic sector and
small and medium sized companies are largely without
this body of knowledge. The European Clinical Research
Infrastructures Network (ECRIN) aims at integrating clini-
cal research in Europe through connecting national net-
works of clinical research centres and clinical trial units.
ECRIN helps investigators and sponsors navigate the
minefield of regulatory issues which differ across boarders
and provide information, consultation and access to ser-
vices necessary to conduct multi-centre clinical studies for
the benefit of patient and citizens [15,16].
ECRIN’s Working Group on regulatory requirements
and interaction with competent authorities had the task
to describe such regulatory requirements and delineate
how to interact with competent authorities in the coun-
tries involved in ECRIN, covering approximately 70% of
the EU population [27]. We therefore conducted a survey
to identify the national requirements for all categories of
clinical research defined and agreed upon by the Work-
ing Group [27]. The present article describest h er e s u l t s
for regulatory requirements during the approval phase of
clinical trials on typical investigational medicinal pro-
ducts, in the ten ECRIN countries.
Methods
In order to analyse the current situation regarding the
regulatory environment during the approval phase of
clinical research in Europe, we designed the survey as
described in a previous publication [27]. The full survey
questionnaire is available as online supplementary mate-
rial http://www.ecrin.org. For the purpose of the survey
we identified seven common definitions for categories of
clinical research, each split into sub-categories [27]. One
of the sub-categories was clinical research assessing typi-
cal investigational medicinal products (Table 1). Typical
investigational medicinal products comprise in general
chemically synthesised drugs, constituting the active sub-
stance within an investigational medicinal product. Such
typical investigational medicinal products are used in
phase I to IV clinical trials independently of the question,
if they have been authorised before for the investigative
or for any other use. Less typical investigational medic-
inal products, mainly biopharmaceutical investigational
medicinal products and a variety of other less typical
investigational medicinal products (Table 1) are also
assessed in phase I to IV clinical trials, but are not dealt
with in the results section of the present article. Our
responses to the survey questionnaire on both typical
investigational medicinal products and less typical inves-
tigational medicinal products have been reported to the
European Commission in 2008 and are available at
http://www.ecrin.org/index.php?id=101[28].
The ECRIN Working Group on regulatory require-
ments and interaction with competent authorities was
composed of two chairpersons and at least two represen-
tatives from each national network from Austria, Den-
mark, France, Germany, Hungary, Ireland, Italy, Spain,
Sweden, and United Kingdom: an expert in the field of
regulations and regulatory requirements and the national
ECRIN European Correspondent (ECRIN staff trained in
clinical research and located in the national coordinating
hubs) [27]. For each of the categories of research, the fol-
lowing questions were asked to the Working Group
members:
- what is the definition of an investigational product?
- what competent authorities exist in your country?
- is a submission to competent authority required
(specify the name of the competent authority and who
is responsible for the submission)?
- what are the timelines?
The Working Group members answered the questions
by consulting national law documents, web-sites, con-
ducting telephone interview s ,e t c .T h er e s p o n s e st ot h e
questionnaire were circulated to the Working Group on
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The results were discussed during several teleconfer-
ences and in face-to-face meetings in Paris (19 and 20
May 2007) and Brussels (19 and 20 May, 2008). More-
over, additional teleconferences were held between one
of the chairs (JD-M) and national representatives in
order to discuss specific national aspects in depth [27].
We also conducted a validation step with the national
representatives from the competent authorities of the
involved countries.
Results
Definition of medicinal product and investigational
medicinal product
The Directive 65/65/EEC [29] and the Directive 2001/20/
EC [17] defines a medicinal product as: “Any substance or
combination of substances presented for treating or pre-
venting disease in human beings or animals. Any sub-
stance or combination of substances which may be
administered to human beings or animals with a view to
making a medical diagnosis or to restoring, correcting or
modifying physiological functions in human beings or in
animals is likewise considered a medicinal product.” The
Directive 65/65/EEC has been repealed by the Directive
2001/83/EC [30].
The Directive 2001/20/EC [17] further gives the follow-
ing definition of the investigational medicinal product: ‘a
pharmaceutical form of an active substance or placebo
being tested, or used as a reference in a clinical trial,
including products already with a marketing authorisation,
but used or assembled (formulated or packaged) in a way
different from the authorised or when used for an
unauthorised indication or when used to gain further
information about the authorised form’.M o r es p e c i f i c
definition of what constitutes an investigational medicinal
product and what constitutes a non-investigational medic-
inal product has been published by the EU Commission
[31].
Our survey collected the definition of an investigational
medicinal product used by the competent authority in the
ten countries (Table 2). Only Austria adopted the defini-
tion directly from the Directive 2001/20/EC. The other
countries adopted definitions that were similar but not
identical, leading to possible difficulties in multinational
trials when a product is considered as an investigational
medicinal product in some countries and not in others
(for instance, on adverse event reporting, labelling, pur-
chasing of the investigational medicinal product). How-
ever, a recent guidance on investigational medicinal
products and non-investigational medicinal products was
issued in March 2011 to further harmonise the national
regulations [32].
Submission of clinical trial protocols on typical investi-
gational medicinal products to the competent authority
in all ten countries require authorisation for clinical trials
using typical investigational medicinal products by com-
petent authorities. However, since April 1
st 2011 in the
UK, the Medicines and Healthcare products Regulatory
Table 1 Definition of clinical trials on typical investigational medicinal products as well as less typical investigational
medicinal products.
Category Includes
Clinical trials on typical investigational medicinal products Phase I to IV clinical trials on medicinal products, that is any substance or
combination of substances presented for treating or preventing disease in
human beings. Any substance or combination of substances which may be
administered to human beings with a view to making a medical diagnosis or
to restoring, correcting or modifying physiological functions in human beings is
likewise considered a medicinal product.
Clinical trials on biopharmaceutical investigational medicinal
products or other less typical investigational medicinal products
Phase I to IV clinical trials on
- Biological medicinal products, i.e., proteins preceded either from biological
material by standardised purification techniques or by recombinant DNA
technologies or hybridoma or monoclonal antibody methods.
- Vaccines.
- Advanced therapy medicinal products, consisting of
- gene therapy medicinal products (human or xenogeneic);
- somatic cell therapy medicinal products (human or xenogeneic);
- tissue engineered product, i.e., a product that contains or consists of
engineered cells or tissues (human or xenogeneic).
- Plasma-derived medicinal products.
- Blood products.
- Radio-pharmaceuticals and precursors.
- Homeopathic medicinal products.
- Herbal medicinal products.
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is equivalent to the risk of usual care-basically trials com-
paring marketed drugs within the licensed indication
[33]. The regulatory authorities, which assess the applica-
tions, are presented in Table 3 and can also be accessed
via the website of the Clinical Trials Facilitation Group
[34]. The sponsor is responsible for the submission of a
clinical trial authorisation application as defined by the
Directive 2001/20/EC [17]. Any substantial amendment
must also be submitted to the competent authority.
Table 2 National definitions of an investigational medicinal product.
Countries Definition of investigational medicinal product
Austria The definition is that of the Directive 2001/20/EC.
Denmark, France, Hungary, Ireland, Italy,
Spain, Sweden, and the UK
The investigational medicinal product is the study drug and the comparator including the placebo
or active drug.
Denmark The rescue drug and all background treatment that directly influences the main efficacy outcomes of
the study are also considered investigational medicinal products.
France The background treatment is also considered an investigational medicinal product if collecting
information on it is one of the objectives of the study.
Germany The investigational medicinal product is a pharmaceutical form of active pharmaceutical substances
and placebos, that is tested in a clinical trial on humans or used as a comparator or that is applied
to induce specific reactions in humans. This includes EU authorised drugs if they are investigated
within a clinical trial, EU authorised drugs if they will be used as comparator, and EU non-authorised
drugs.
Italy The drugs which are not the direct subject of the experimental design, but their use is considered in
the protocol, are also considered investigational medicinal products:
1. Drugs with market authorisation, used according to the indications, included in the protocol as
needed to the success of the trial, such as drugs to prevent or treat side effects of the
investigational medicinal product.
2. Drugs with market authorisation, used outside the approved indication.
3. Drugs without market authorisation, but with market authorisation in other countries of the EC,
used within or without the approved indication.
4. Challenge agents, i.e., drugs that are used to induce physiological reactions needed to evaluate
the effect of the investigational medicinal product.
The rescue drug, and background treatments are not investigational medicinal products.
Spain Background treatment, the rescue drug, the challenge agent and the medicine used to assess the
primary endpoint, if not authorised in any EU country, or when authorised and used for non-
authorised indications are also considered investigational medicinal product.
Sweden The drugs used to assess outcome measures are also considered investigational medicinal products.
This includes already approved drugs, which have been formulated differently or are used outside
their approved indication, or used to gain additional knowledge about the approved indication.
Table 3 Competent authorities for clinical trials on typical investigational medicinal products in ten EU countries.
Country Competent authorities for typical investigational medicinal products
Austria The “Bundesamt für Sicherheit im Gesundheitswesen” (BASG, Federal Office for Health Safety) [42], supported by the Austrian Medicines
Agency, AGES PharmMed [43].
Denmark The Danish Medicines Agency [44].
France Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) [45].
Germany The Federal Institute for Drugs and Medical Devices (BfArM) [46], and the investigator has also to submit the protocol to the local
competent authority.
Hungary The National Institute of Pharmacy (NIP) [47].
Ireland The Irish Medicines Board (IMB) [48].
Italy All clinical trials have to be declared on the database of the Agenzia Italiana del Farmaco (AIFA) (Osservatorio Nazionale Sulla
Sperimetazione Clinical Dei Medicinali; National Monitoring Centre for Clinical Trials) [49]. For phase I clinical trials, the competent
authority is the Istituto Superiore della Sanita (ISS) [50]. For phase II, III and IV clinical trials, the competent authority is the director of the
Public Health Facility [51].
Spain The Spanish Agency for Medicines and Medical Devices (AEMPS) [52]. Performance of clinical trial on medicinal products not authorised in
the EU and containing any active substance not included in any authorised medicinal product in Spain requires an additional application
for a ‘product under clinical research qualification’ (PEI).
Sweden The Medical Products Agency (MPA) [53].
The UK The Medicines and Healthcare Products Regulatory Agency (MHRA) [54].
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application by the competent authority are 30 days from
receipt of valid application to accept, accept with condi-
tions, or reject. The final decision is taken within
60 days of the original request. Only one cycle of corre-
spondence on any queries, which arise from the assess-
ment, is allowed. If no answer is received from the
sponsor or if the answer is not acceptable, the applica-
tion is refused. Opportunities exist for dialogue with the
national regulatory authorities to ensure the tasks of the
sponsor and questions to the sponsor are adequately
addressed. Divergences, however, still exist in the docu-
mentation and national requirements, and in the deci-
sions of the national competent authorities. For this
reason, the heads of medicines agencies implemented in
2010 the Voluntary Harmonisation Procedure, offering
the possibility to apply through a single dossier and to
undergo coordinated review for multinational trials [35].
Discussion
Our results show that clinical trials using typical investi-
gational medicinal products require authorisation from a
competent authority in each of the ten EU countries
surveyed. The opinion of the competent authorities is
communicated to the trial sponsor within the same
timelines in all ten countries surveyed. This is a clear
indication that the requirements of the Directive 2001/
20/EC [17] have been relatively uniformly adopted for
this type of clinical research in these ten countries, and
their application structure, that is the institutions one
has to apply to, is comparable but not identical. The
overall result of the implementation of the Directive
2001/20/EC is harmonisation of requirements for typical
investigational medicinal products and a navigable land-
scape for the applicant.
In practice, this harmonisation of regulatory require-
ments is in fact specific to a certain type of investiga-
tional medicinal product, which we name ‘typical
investigational medicinal product’. In practice, the regu-
latory requirements are not harmonised for a number of
other important investigational medicinal products,
which we name ‘less typical investigational medicinal
products’ [27], including different sub-categories of
medicinal product as listed and described in the Direc-
tive 2003/63/EC [36]:
○ Biological medicinal products, i.e., proteins pre-
ceded either from biological material by standardised
purification techniques or by recombinant DNA
technologies or hybridoma or monoclonal antibody
methods.
○ Vaccines.
○ Advanced therapy medicinal products, consisting
of
- gene therapy medicinal products (human or
xenogeneic);
- somatic cell therapy medicinal products
(human or xenogeneic);
- tissue engineered product, i.e., a product that
contains or consists of engineered cells or tissues
(human or xenogeneic).
○ Plasma-derived medicinal products.
○ Blood products.
○ Radio-pharmaceuticals and precursors.
○ Homeopathic medicinal products.
○ Herbal medicinal products.
The seemingly uniform definition of an investigational
medicinal product from the Directive 2001/20/EC [17]
did not prevent many sub-categories of medicinal pro-
ducts to be selected out across the EU. This gave rise to
specific regulatory requirements across EU Members
States. These specific regulatory requirements have
increased the complexity of the national clinical trial
regulation in the EU [28] and participated in the crea-
tion of a chaotic regulatory environment which threa-
tens ethical and fairness considerations both to patients
and researchers [15,16,18-26]. The chaotic regulatory
environment, in which intervention decides regulation
[28], alienate researchers from understanding the basis
for implementing interventions into clinical practice and
this puts patients at risk.
The definition of a ‘medicinal product’ in the Directive
65/65/EEC [29] and reiterated in the Directive 2001/20/
EC [17] and the Directive 2001/83/EC [30] is much
clearer, comprehensive, and fairer than the definition of
an ‘investigational medicinal product’ in the Directive
2001/20/EC [17]. The former Directives defines a medic-
inal product as: “a) Any substance or combination of sub-
stances presented as having properties for treating or
preventing disease in human beings; or b) Any substance
or combination of substances which may be used in or
administered to human beings either with a view to
restoring, correcting or modifying physiological functions
by exerting a pharmacological, immunological or meta-
bolic action, or to making a medical diagnosis.” However,
the Directive 2001/20/EC [17] defines an investigational
medicinal product as: “a pharmaceutical form of an active
substance or placebo being tested or used as a reference
in a clinical trial, including products already with a mar-
keting authorisation but used or assembled (formulated
or packaged) in a way different from the authorised form,
or when used for an unauthorised indication, or when
used to gain further information about the authorised
form”.
We would very much have preferred that the defini-
tion of an ‘investigational medicinal product’ built upon
the wording for the definition of a medicinal product
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EC [17], and Directive 2001/83/EC [30], e.g.,: a medic-
inal product (as defined by the three cited Directives)
with potential beneficial properties being tested, or used
as a comparator reference, in a clinical trial. Including
products already with a marketing authorisation but
used or assembled (formulated or packaged) in a way
different from the authorised form, or when used for an
unauthorised indication, or when used to gain further
information about the authorised form.
There is a huge amount of legislation and guidance
pertinent to clinical research in the EU as well as in the
different member states; this makes it difficult to have
an overall view of the full regulatory requirements
[17,30,37-39]. An overview of the kind presented here is
novel and provides a necessary overview of the regula-
tory framework within the ten EU countries participat-
ing in ECRIN during the 2006 to 2008 period regarding
typical investigational medicinal products. To our
knowledge this is the first time that a survey about the
regulatory basis for typical investigational medicinal pro-
ducts has been conducted in such depth.
The present study has a number of weaknesses. First,
we only assessed ten countries. Although we covered
the majority of the EU population (70%) there are still
17 EU countries not considered. ECRIN is in the pro-
cess of linking to the national clinical trial networks in
these countries and ECRIN will assess their regulatory
environment regarding typical investigational medicinal
products [30]. Second, we only assessed the regulatory
authority structure during the approval phase of the
trial in the surveyed countries, not how the regulatory
process was working during the conduct and termina-
tion of the trial. Third, we did not go into details about
how other aspects of the Directive 2001/20/EC, e.g.,
good clinical practice were implemented and functioned.
Fourth, we only concentrated on how the typical investi-
gational medicinal product was handled in the national
laws and regulations. The latter also explains why the
present study observes relative harmonisation compared
to other assessments of the implementation of the
Directive 2001/20/EC, which found divergences at the
national level and increased complexity in conducting
multinational clinical trials [18-26]. In our assessments
of less typical investigational medicinal products we
observed substantial heterogeneity [28].
Compared to typical investigational medicinal pro-
ducts, the regulatory landscape is not so navigable for
other categories of clinical research [27,28]. Although,
strictly speaking, all investigational medicinal products
are legislated for under the 2001/20/EC Directive and
the definitions therein, less typical investigational medic-
inal products such as biopharmaceutical investigational
medicinal products or other less typical investigational
medicinal products investigating gene therapy, tissue
engineering, cell therapy, blood-derived products, mono-
clonal antibodies, recombinant proteins, vaccines trials,
etc [27] all necessitate additional regulatory require-
ments, which vary across Europe [28]. In short, the reg-
ulatory environment is much more heterogeneous and
thereby problematic for academic trialists and small and
medium sized companies regarding other medical inter-
ventions [28]. This puts at stake the interests of patients
[25,26].
Regulatory requirements should be in place with the
principal objective of protecting the participants and
ensuring their safety, and that regulatory requirements
can be adjusted according to the risk of the trial [28].
However, it appears that regulatory requirements in dif-
ferent Member States are driven trivially by the category
of the intervention and not on the overall risk of the
trial [27,28]. An innovative biopharmaceutical product
could be equally as high risk as an innovative surgery.
Risk is a complex and multi-faceted concept and can be
influenced by, among other things, vested interests
(sponsorship), the size of the trial (feasibility), the num-
ber of centres (feasibility and quality assurance), and
crucially, and the nature of the experimental and control
interventions [40]. Therefore, a risk based approach
rather than an approach depending on type of investiga-
tional medicinal product seems a better way to deter-
mine the need for security and monitoring in a given
clinical trial [24,41]. Interestingly a pilot initiative
steered by the MHRA, the MRC, and the Department of
Health started in April 2011 the UK, defining risk
assessment and risk-adapted supervision in the frame-
work of the Directive 2001/20/EC [33].
The Voluntary Harmonisation Procedure implemented
since 2010 represents a substantial progress for the regula-
tory supervision, allowing coordinated review for multina-
tional trials [34]. We ought to go further and implement a
single application and authorisation process for all clinical
trials, by which the sponsor submits one electronic appli-
cation which is accessible by the competent authorities,
the ethics committees, and the public, with harmonised
definitions of the roles of the ethics committees (protec-
tion of the trial participants) and of the competent autho-
rities (assessment of the health product) [28,35].
Conclusions
The Directive 2001/20/EC seems to have delivered on its
harmonisation objective regarding typical investigational
medicinal products during the application phase; we
commend this achievement. However, it only benefits
sponsors and investigators conducting clinical trials on
typical investigational medicinal products. We cannot
have a hierarchical system where the regulatory require-
ments are relatively harmonised and navigable for one set
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fic barriers for other clinical interventions [28]. Our
results show that the harmonisation is limited to the field
of typical investigational medicinal products [28]; this
harmonisation does not even encompass all investiga-
tional medicinal products that Directive 2001/20/EC
itself defined. Only a European regulation, binding in
their entirety to and immediately applicable in all EU
member states, can truly harmonize the rules for clinical
research in Europe. De-fragmentation of the authorisa-
tion procedure as well as risk-based clinical trial supervi-
sion and monitoring processes should be key elements in
such new legislation.
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